Zerion Pharma A/SAktiv

Zerion Pharma A/S (“Zerion” or “the Company”) is a drug development company, based in Copenhagen. The Company was founded in January 2019 as a spinout from the University of Copenhagen based on a decade of research. ​ ​Zerion has developed a formulation technology, Dispersome®, that enables poorly soluble drugs to become effective pharmaceutical products. The Company applies the technology to 1) improve existing drug products, thereby building its own pipeline of product candidates and 2) partner with major pharmaceutical and biotech companies to solve problems with solubility and bioavailability in their new pharmaceutical candidates (NCEs). ​​Zerion’s R&D activities comprise firstly in-house lab work with the aim to develop better formulations of new and existing drugs. The Company’s research labs are located at the incubator centre, Symbion, where the Company employs about 10 scientists and technicians. Secondly, Zerion conducts external pre-clinical and eventually clinical studies with selected drug candidates which incorporate the Dispersome® technology.

Development in activities and financesDuring 2025, the Company made significant progress in its R&D and commercial activities. Zerion and Hovione Farmaciência, S.A.(“HOVIONE”) continued their partnership to accelerate the development of the Dispersome® technology platform. HOVIONE completed a human study testing a Dispersome formulation of a nutraceutical against the best commercially available products with good results. ​ ​Zerion’s partner Insud Pharma completed a clinical study of a Dispersome drug product that confirmed the performance of the Dispersome product. Zerion’s partnership with the Brazilian company Aché progressed very well and a new product was included in the collaboration during the year. ​Zerion continued working on other partner projects and also secured additional partner projects during 2025. Overall, substantial advances were made towards the first Dispersome products to the market. ​ ​The Company also successfully applied for two Eurostar projects, in collaboration with two German partners and one Belgium partner, respectively. The two projects will contribute a total of € 600,000 to Zerion in soft funding during 2026 and 2027. ​​In the beginning of 2025, the Company raised DKK 8.7 million in a share issue to both existing and new shareholders. In November 2025, convertible loan notes of DKK 2.7 million were secured from the existing shareholders. ​​​​​​​​

Uddrag af ledelsesberetningen i den seneste årsrapport.